News | July 05, 2007

Toshiba to Offer New PV-CTA Training Course

July, 6, 2007 – Toshiba America Medical Systems, Inc. announced a partnership with CVCTA Education to provide a Peripheral Vascular CTA (PV-CTA) training course in a move to strengthen its position in medical education and improved patient care.
This course will be the first of its kind to exceed current ACCF/AHA Level 2 requirements in the ACCF/AHA Clinical Competence Statement on Cardiac Imaging with Computed Tomography and Magnetic Resonance.
“PV-CTA is one of the most accurate and important non-invasive diagnostic tools available to detect PVD in patients reporting symptoms and in those who are asymptomatic,” said Doug Ryan, senior director, CT Business Unit. “Partnering with CVCTA Education to offer a comprehensive PV-CTA educational course is a step toward ensuring that PVD is properly detected and treated.”
The PV-CTA training course will be offered at CVCTA Training Centers in San Francisco, New York and Houston, several times per month with the first course starting in September. The course will use a blend of online learning and in-person training on Toshiba’s leading Aquilion CT scanners. Students will complete six hours of online didactics covering a review of anatomy and function, as well as findings and reporting. Also, in one day of hands-on workstation training, the students will be mentored on more than 25 cases of varying pathology. Students also will work on more than 75 cases via CVCTA’s proprietary MedMind CTA training software.
Created by Dr. Peter Fail from the Cardiovascular Institute of the South and Dr. Tony DeFrance from CVCTA, the PV-CTA course will provide students with more than 100 mentored cases with a wide variety of pathology, therefore exceeding the anticipated Level 2 requirements set by the ACCF and AHA. In total, the student will receive 40 hours of CME credit.
“PV-CTA will play an important role in helping imaging centers and hospitals educate the community on the emerging information and issues regarding the overall impact of PVD and the value of this diagnostic tool,” said Tony DeFrance, M.D., medical director of CVCTA Education.

For more information: www.medical.toshiba.com and www.cvcta.com


Related Content

News | Peripheral Artery Disease (PAD)

Dec. 13, 2024 – Sensome has announced positive results from two studies of its Clotild Smart Guidewire System ...

Home December 16, 2024
Home
News | Peripheral Artery Disease (PAD)

Nov. 18, 2024 — In November, Esperion presented an analysis from the CLEAR Outcomes study focused on patients with ...

Home December 03, 2024
Home
News | Peripheral Artery Disease (PAD)

Nov. 4, 2024 — Royal Philips recently announced enrollment of the first patient in the U.S. THOR IDE clinical trial ...

Home November 08, 2024
Home
News | Peripheral Artery Disease (PAD)

Sept. 16, 2024 – Shockwave Medical, Inc., part of Johnson & Johnson MedTech, has announced the full U.S. launch of the ...

Home September 16, 2024
Home
News | Peripheral Artery Disease (PAD)

Sept. 1, 2024 — September is Peripheral Artery Disease (PAD) Awareness Month, a time to educate and empower people to ...

Home September 04, 2024
Home
News | Peripheral Artery Disease (PAD)

May 16, 2024 — Timely diagnosis and proper management of peripheral artery disease (PAD), including coordinated care ...

Home May 16, 2024
Home
News | Peripheral Artery Disease (PAD)

May 8, 2024 — In a groundbreaking development, a study published in the Journal of Vascular Surgery reveals for the ...

Home May 08, 2024
Home
News | Peripheral Artery Disease (PAD)

March 20, 2024 — Biotronik has been granted Breakthrough Device Designation (BDD) from the US Food and Drug ...

Home March 20, 2024
Home
News | Peripheral Artery Disease (PAD)

February 12, 2024 — Sensome, a company pioneering the connected medical device revolution with the world’s smallest ...

Home February 12, 2024
Home
News | Peripheral Artery Disease (PAD)

November 10, 2023 —Getinge announced commercial availability of the iCast covered stent system in the United States for ...

Home November 10, 2023
Home
Subscribe Now